메뉴 건너뛰기




Volumn 56, Issue 4, 2008, Pages 195-204

Thromboembolic risk associated with use of angiogenesis inhibitors used for the treatment of cancers;Risque thromboembolique des thérapeutiques antiangiogéniques utilisées dans les cancers

Author keywords

Angiogenesis; Antiangiogenic; Cancer; Myeloma; Thalidomide; Thrombosis; VEGF

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; ACETYLSALICYLIC ACID; ANGIOGENESIS INHIBITOR; ANTICOAGULANT AGENT; CEDIRANIB; CHR 258; CORTICOSTEROID; ERYTHROPOIETIN; IMMUNOMODULATING AGENT; INTERLEUKIN 1; INTERLEUKIN 6; KRN 951; L SELECTIN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; PAZOPANIB; SEMAXANIB; THALIDOMIDE; VANDETANIB; VASCULOTROPIN; VATALANIB;

EID: 44449135859     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2008.02.013     Document Type: Review
Times cited : (7)

References (68)
  • 3
    • 0035883101 scopus 로고    scopus 로고
    • Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes
    • Raza A., Meyer P., Dutt D., Zorat F., Lisak L., Nascimben F., et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98 (2001) 958-965
    • (2001) Blood , vol.98 , pp. 958-965
    • Raza, A.1    Meyer, P.2    Dutt, D.3    Zorat, F.4    Lisak, L.5    Nascimben, F.6
  • 5
    • 0036464605 scopus 로고    scopus 로고
    • Efficacy and safety of thalidomide in patients with acute myeloid leukemia
    • Steins M.B., Padro T., Bieker R., Ruiz S., Kropff M., Kienast J., et al. Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood 99 (2002) 834-839
    • (2002) Blood , vol.99 , pp. 834-839
    • Steins, M.B.1    Padro, T.2    Bieker, R.3    Ruiz, S.4    Kropff, M.5    Kienast, J.6
  • 6
    • 0034928836 scopus 로고    scopus 로고
    • Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia
    • Barosi G., Grossi A., Comotti B., Musto P., Gamba G., and Marchetti M. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 114 (2001) 78-83
    • (2001) Br J Haematol , vol.114 , pp. 78-83
    • Barosi, G.1    Grossi, A.2    Comotti, B.3    Musto, P.4    Gamba, G.5    Marchetti, M.6
  • 7
    • 5344258973 scopus 로고    scopus 로고
    • Adverse effects of thalidomide administration in patients with neoplastic diseases
    • Dimopoulos M.A., and Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 117 (2004) 508-515
    • (2004) Am J Med , vol.117 , pp. 508-515
    • Dimopoulos, M.A.1    Eleutherakis-Papaiakovou, V.2
  • 8
    • 0035469858 scopus 로고    scopus 로고
    • Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy
    • Zangari M., Anaissie E., Barlogie B., Badros A., Desikan R., Gopal A.V., et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98 (2001) 1614-1615
    • (2001) Blood , vol.98 , pp. 1614-1615
    • Zangari, M.1    Anaissie, E.2    Barlogie, B.3    Badros, A.4    Desikan, R.5    Gopal, A.V.6
  • 9
    • 33745291997 scopus 로고    scopus 로고
    • Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations
    • Hussein M.A. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb Haemost 95 (2006) 924-930
    • (2006) Thromb Haemost , vol.95 , pp. 924-930
    • Hussein, M.A.1
  • 11
  • 13
    • 0037370067 scopus 로고    scopus 로고
    • Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer
    • Horne III M.K., Figg W.D., Arlen P., Gulley J., Parker C., Lakhani N., et al. Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer. Pharmacotherapy 23 (2003) 315-318
    • (2003) Pharmacotherapy , vol.23 , pp. 315-318
    • Horne III, M.K.1    Figg, W.D.2    Arlen, P.3    Gulley, J.4    Parker, C.5    Lakhani, N.6
  • 14
    • 0037393945 scopus 로고    scopus 로고
    • Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha
    • Steurer M., Sudmeier I., Stauder R., and Gastl G. Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha. Br J Haematol 121 (2003) 101-103
    • (2003) Br J Haematol , vol.121 , pp. 101-103
    • Steurer, M.1    Sudmeier, I.2    Stauder, R.3    Gastl, G.4
  • 15
    • 0141452131 scopus 로고    scopus 로고
    • Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin
    • Wun T., Law L., Harvey D., Sieracki B., Scudder S.A., and Ryu J.K. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 98 (2003) 1514-1520
    • (2003) Cancer , vol.98 , pp. 1514-1520
    • Wun, T.1    Law, L.2    Harvey, D.3    Sieracki, B.4    Scudder, S.A.5    Ryu, J.K.6
  • 17
    • 4644220200 scopus 로고    scopus 로고
    • Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group study
    • Lavey R.S., Liu P.Y., Greer B.E., Robinson III W.R., Chang P.C., Wynn R.B., et al. Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group study. Gynecol Oncol 95 (2004) 145-151
    • (2004) Gynecol Oncol , vol.95 , pp. 145-151
    • Lavey, R.S.1    Liu, P.Y.2    Greer, B.E.3    Robinson III, W.R.4    Chang, P.C.5    Wynn, R.B.6
  • 18
    • 0033168605 scopus 로고    scopus 로고
    • Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha
    • Corral L.G., Haslett P.A., Muller G.W., Chen R., Wong L.M., Ocampo C.J., et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163 (1999) 380-386
    • (1999) J Immunol , vol.163 , pp. 380-386
    • Corral, L.G.1    Haslett, P.A.2    Muller, G.W.3    Chen, R.4    Wong, L.M.5    Ocampo, C.J.6
  • 20
    • 0035195019 scopus 로고    scopus 로고
    • Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
    • Gupta D., Treon S.P., Shima Y., Hideshima T., Podar K., Tai Y.T., et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15 (2001) 1950-1961
    • (2001) Leukemia , vol.15 , pp. 1950-1961
    • Gupta, D.1    Treon, S.P.2    Shima, Y.3    Hideshima, T.4    Podar, K.5    Tai, Y.T.6
  • 21
    • 27744492561 scopus 로고    scopus 로고
    • Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
    • Rajkumar S.V., Hayman S.R., Lacy M.Q., Dispenzieri A., Geyer S.M., Kabat B., et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106 (2005) 4050-4053
    • (2005) Blood , vol.106 , pp. 4050-4053
    • Rajkumar, S.V.1    Hayman, S.R.2    Lacy, M.Q.3    Dispenzieri, A.4    Geyer, S.M.5    Kabat, B.6
  • 22
    • 33646494190 scopus 로고    scopus 로고
    • Lenalidomide and venous thrombosis in multiple myeloma
    • Knight R., DeLap R.J., and Zeldis J.B. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354 (2006) 2079-2080
    • (2006) N Engl J Med , vol.354 , pp. 2079-2080
    • Knight, R.1    DeLap, R.J.2    Zeldis, J.B.3
  • 23
    • 3242787246 scopus 로고    scopus 로고
    • Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor
    • Tobu M., Iqbal O., Fareed D., Chatha M., Hoppensteadt D., Bansal V., et al. Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor. Clin Appl Thromb Hemost 10 (2004) 225-232
    • (2004) Clin Appl Thromb Hemost , vol.10 , pp. 225-232
    • Tobu, M.1    Iqbal, O.2    Fareed, D.3    Chatha, M.4    Hoppensteadt, D.5    Bansal, V.6
  • 24
    • 4344693453 scopus 로고    scopus 로고
    • Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma
    • Schey S.A., Fields P., Bartlett J.B., Clarke I.A., Ashan G., Knight R.D., et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 22 (2004) 3269-3276
    • (2004) J Clin Oncol , vol.22 , pp. 3269-3276
    • Schey, S.A.1    Fields, P.2    Bartlett, J.B.3    Clarke, I.A.4    Ashan, G.5    Knight, R.D.6
  • 25
    • 16244363678 scopus 로고    scopus 로고
    • Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis
    • Streetly M., Hunt B.J., Parmar K., Jones R., Zeldis J., and Schey S. Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis. Eur J Haematol 74 (2005) 293-296
    • (2005) Eur J Haematol , vol.74 , pp. 293-296
    • Streetly, M.1    Hunt, B.J.2    Parmar, K.3    Jones, R.4    Zeldis, J.5    Schey, S.6
  • 26
    • 33751074915 scopus 로고    scopus 로고
    • Myeloma, thalidomide and thrombosis
    • Honemann D., and Prince H.M. Myeloma, thalidomide and thrombosis. Leuk Lymphoma 47 (2006) 2273-2275
    • (2006) Leuk Lymphoma , vol.47 , pp. 2273-2275
    • Honemann, D.1    Prince, H.M.2
  • 27
    • 33750067977 scopus 로고    scopus 로고
    • Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102)
    • Krown S.E., Niedzwiecki D., Hwu W.J., Hodgson L., Houghton A.N., and Haluska F.G. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer 107 (2006) 1883-1890
    • (2006) Cancer , vol.107 , pp. 1883-1890
    • Krown, S.E.1    Niedzwiecki, D.2    Hwu, W.J.3    Hodgson, L.4    Houghton, A.N.5    Haluska, F.G.6
  • 29
    • 33748700214 scopus 로고    scopus 로고
    • Acquired activated protein C resistance and thrombosis in multiple myeloma patients
    • Jimenez-Zepeda V.H., and Dominguez-Martinez V.J. Acquired activated protein C resistance and thrombosis in multiple myeloma patients. Thromb J 4 (2006) 11
    • (2006) Thromb J , vol.4 , pp. 11
    • Jimenez-Zepeda, V.H.1    Dominguez-Martinez, V.J.2
  • 30
    • 0642341991 scopus 로고    scopus 로고
    • Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment
    • Minnema M.C., Fijnheer R., De Groot P.G., and Lokhorst H.M. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 1 (2003) 445-449
    • (2003) J Thromb Haemost , vol.1 , pp. 445-449
    • Minnema, M.C.1    Fijnheer, R.2    De Groot, P.G.3    Lokhorst, H.M.4
  • 31
    • 0036526384 scopus 로고    scopus 로고
    • Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications
    • Zangari M., Saghafifar F., Anaissie E., Badros A., Desikan R., Fassas A., et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 13 (2002) 187-192
    • (2002) Blood Coagul Fibrinolysis , vol.13 , pp. 187-192
    • Zangari, M.1    Saghafifar, F.2    Anaissie, E.3    Badros, A.4    Desikan, R.5    Fassas, A.6
  • 32
    • 0036645524 scopus 로고    scopus 로고
    • Endothelial dysfunction in antiangiogenesis-associated thrombosis
    • Kaushal V., Kohli M., Zangari M., Fink L., and Mehta P. Endothelial dysfunction in antiangiogenesis-associated thrombosis. J Clin Oncol 20 (2002) 3042-3043
    • (2002) J Clin Oncol , vol.20 , pp. 3042-3043
    • Kaushal, V.1    Kohli, M.2    Zangari, M.3    Fink, L.4    Mehta, P.5
  • 33
    • 0029767998 scopus 로고    scopus 로고
    • Apoptosis is associated with increased cell surface tissue factor procoagulant activity
    • Greeno E.W., Bach R.R., and Moldow C.F. Apoptosis is associated with increased cell surface tissue factor procoagulant activity. Lab Invest 75 (1996) 281-289
    • (1996) Lab Invest , vol.75 , pp. 281-289
    • Greeno, E.W.1    Bach, R.R.2    Moldow, C.F.3
  • 34
    • 0035724408 scopus 로고    scopus 로고
    • Thrombogenic role of cells undergoing apoptosis
    • Wang J., Weiss I., Svoboda K., and Kwaan H.C. Thrombogenic role of cells undergoing apoptosis. Br J Haematol 115 (2001) 382-391
    • (2001) Br J Haematol , vol.115 , pp. 382-391
    • Wang, J.1    Weiss, I.2    Svoboda, K.3    Kwaan, H.C.4
  • 35
    • 3242760702 scopus 로고    scopus 로고
    • First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma
    • Cavo M., Zamagni E., Tosi P., Cellini C., Cangini D., Tacchetti P., et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 89 (2004) 826-831
    • (2004) Haematologica , vol.89 , pp. 826-831
    • Cavo, M.1    Zamagni, E.2    Tosi, P.3    Cellini, C.4    Cangini, D.5    Tacchetti, P.6
  • 36
    • 33751103917 scopus 로고    scopus 로고
    • Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism
    • Miller K.C., Padmanabhan S., Dimicelli L., Depaolo D., Landrigan B., Yu J., et al. Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. Leuk Lymphoma 47 (2006) 2339-2343
    • (2006) Leuk Lymphoma , vol.47 , pp. 2339-2343
    • Miller, K.C.1    Padmanabhan, S.2    Dimicelli, L.3    Depaolo, D.4    Landrigan, B.5    Yu, J.6
  • 37
    • 33646883735 scopus 로고    scopus 로고
    • Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis
    • Ikhlaque N., Seshadri V., Kathula S., and Baumann M.A. Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. Am J Hematol 81 (2006) 420-422
    • (2006) Am J Hematol , vol.81 , pp. 420-422
    • Ikhlaque, N.1    Seshadri, V.2    Kathula, S.3    Baumann, M.A.4
  • 38
    • 33746593667 scopus 로고    scopus 로고
    • Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide
    • Palumbo A., Rus C., Zeldis J.B., Rodeghiero F., and Boccadoro M. Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. J Thromb Haemost 4 (2006) 1842-1845
    • (2006) J Thromb Haemost , vol.4 , pp. 1842-1845
    • Palumbo, A.1    Rus, C.2    Zeldis, J.B.3    Rodeghiero, F.4    Boccadoro, M.5
  • 39
    • 4544332965 scopus 로고    scopus 로고
    • Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation
    • Zangari M., Barlogie B., Anaissie E., Saghafifar F., Eddlemon P., Jacobson J., et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 126 (2004) 715-721
    • (2004) Br J Haematol , vol.126 , pp. 715-721
    • Zangari, M.1    Barlogie, B.2    Anaissie, E.3    Saghafifar, F.4    Eddlemon, P.5    Jacobson, J.6
  • 40
    • 19944368366 scopus 로고    scopus 로고
    • Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy
    • Minnema M.C., Breitkreutz I., Auwerda J.J., van der H.B., Cremer F.W., van Marion A.M., et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 18 (2004) 2044-2046
    • (2004) Leukemia , vol.18 , pp. 2044-2046
    • Minnema, M.C.1    Breitkreutz, I.2    Auwerda, J.J.3    van der, H.B.4    Cremer, F.W.5    van Marion, A.M.6
  • 41
    • 28544436819 scopus 로고    scopus 로고
    • The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma
    • Baz R., Li L., Kottke-Marchant K., Srkalovic G., McGowan B., Yiannaki E., et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 80 (2005) 1568-1574
    • (2005) Mayo Clin Proc , vol.80 , pp. 1568-1574
    • Baz, R.1    Li, L.2    Kottke-Marchant, K.3    Srkalovic, G.4    McGowan, B.5    Yiannaki, E.6
  • 42
    • 33845442041 scopus 로고    scopus 로고
    • Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer
    • Bennett C.L., Angelotta C., Yarnold P.R., Evens A.M., Zonder J.A., Raisch D.W., et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA 296 (2006) 2558-2560
    • (2006) JAMA , vol.296 , pp. 2558-2560
    • Bennett, C.L.1    Angelotta, C.2    Yarnold, P.R.3    Evens, A.M.4    Zonder, J.A.5    Raisch, D.W.6
  • 43
    • 33846318493 scopus 로고    scopus 로고
    • Risk of thrombosis with lenalidomide and its prevention with aspirin
    • Hirsh J. Risk of thrombosis with lenalidomide and its prevention with aspirin. Chest 131 (2007) 275-277
    • (2007) Chest , vol.131 , pp. 275-277
    • Hirsh, J.1
  • 45
    • 0037775584 scopus 로고    scopus 로고
    • Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer
    • Lee A.Y., Levine M.N., Baker R.I., Bowden C., Kakkar A.K., Prins M., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 (2003) 146-153
    • (2003) N Engl J Med , vol.349 , pp. 146-153
    • Lee, A.Y.1    Levine, M.N.2    Baker, R.I.3    Bowden, C.4    Kakkar, A.K.5    Prins, M.6
  • 46
    • 0037067889 scopus 로고    scopus 로고
    • Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study
    • Meyer G., Marjanovic Z., Valcke J., Lorcerie B., Gruel Y., Solal-Celigny P., et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162 (2002) 1729-1735
    • (2002) Arch Intern Med , vol.162 , pp. 1729-1735
    • Meyer, G.1    Marjanovic, Z.2    Valcke, J.3    Lorcerie, B.4    Gruel, Y.5    Solal-Celigny, P.6
  • 47
    • 0025141337 scopus 로고
    • What is the evidence that tumors are angiogenesis dependent?
    • Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 82 (1990) 4-6
    • (1990) J Natl Cancer Inst , vol.82 , pp. 4-6
    • Folkman, J.1
  • 48
    • 0030576517 scopus 로고    scopus 로고
    • Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
    • Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
    • (1996) Cell , vol.86 , pp. 353-364
    • Hanahan, D.1    Folkman, J.2
  • 49
    • 0037208589 scopus 로고    scopus 로고
    • Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
    • Kabbinavar F., Hurwitz H.I., Fehrenbacher L., Meropol N.J., Novotny W.F., Lieberman G., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 (2003) 60-65
    • (2003) J Clin Oncol , vol.21 , pp. 60-65
    • Kabbinavar, F.1    Hurwitz, H.I.2    Fehrenbacher, L.3    Meropol, N.J.4    Novotny, W.F.5    Lieberman, G.6
  • 50
    • 17844373871 scopus 로고    scopus 로고
    • Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy
    • Shah M.A., Ilson D., and Kelsen D.P. Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol 23 (2005) 2574-2576
    • (2005) J Clin Oncol , vol.23 , pp. 2574-2576
    • Shah, M.A.1    Ilson, D.2    Kelsen, D.P.3
  • 51
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    • Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
    • (2004) N Engl J Med , vol.350 , pp. 2335-2342
    • Hurwitz, H.1    Fehrenbacher, L.2    Novotny, W.3    Cartwright, T.4    Hainsworth, J.5    Heim, W.6
  • 52
    • 20544478429 scopus 로고    scopus 로고
    • Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial
    • Kabbinavar F.F., Schulz J., McCleod M., Patel T., Hamm J.T., Hecht J.R., et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23 (2005) 3697-3705
    • (2005) J Clin Oncol , vol.23 , pp. 3697-3705
    • Kabbinavar, F.F.1    Schulz, J.2    McCleod, M.3    Patel, T.4    Hamm, J.T.5    Hecht, J.R.6
  • 53
    • 2942621888 scopus 로고    scopus 로고
    • Bevacizumab in the treatment of breast cancer: rationale and current data
    • Rugo H.S. Bevacizumab in the treatment of breast cancer: rationale and current data. Oncologist 9 Suppl. 1 (2004) 43-49
    • (2004) Oncologist , vol.9 , Issue.SUPPL. 1 , pp. 43-49
    • Rugo, H.S.1
  • 54
    • 2942526896 scopus 로고    scopus 로고
    • Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?
    • Herbst R.S., and Sandler A.B. Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?. Oncologist 9 Suppl 1 (2004) 19-26
    • (2004) Oncologist , vol.9 , Issue.SUPPL. 1 , pp. 19-26
    • Herbst, R.S.1    Sandler, A.B.2
  • 55
    • 24344442899 scopus 로고    scopus 로고
    • Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab
    • Scappaticci F.A., Fehrenbacher L., Cartwright T., Hainsworth J.D., Heim W., Berlin J., et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91 (2005) 173-180
    • (2005) J Surg Oncol , vol.91 , pp. 173-180
    • Scappaticci, F.A.1    Fehrenbacher, L.2    Cartwright, T.3    Hainsworth, J.D.4    Heim, W.5    Berlin, J.6
  • 56
    • 33846484966 scopus 로고    scopus 로고
    • Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma
    • Frangie C., Lefaucheur C., Medioni J., Jacquot C., Hill G.S., and Nochy D. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 8 (2007) 177-178
    • (2007) Lancet Oncol , vol.8 , pp. 177-178
    • Frangie, C.1    Lefaucheur, C.2    Medioni, J.3    Jacquot, C.4    Hill, G.S.5    Nochy, D.6
  • 57
    • 33845353863 scopus 로고    scopus 로고
    • Chemotherapy with bevacizumab, irinotecan, 5-fluorouracil and leucovorin (IFL) associated with a large, embolizing thrombus in the thoracic aorta
    • Yoon S., Schmassmann-Suhijar D., Zuber M., Konietzny P., and Schmassmann A. Chemotherapy with bevacizumab, irinotecan, 5-fluorouracil and leucovorin (IFL) associated with a large, embolizing thrombus in the thoracic aorta. Ann Oncol 17 (2006) 1851-1852
    • (2006) Ann Oncol , vol.17 , pp. 1851-1852
    • Yoon, S.1    Schmassmann-Suhijar, D.2    Zuber, M.3    Konietzny, P.4    Schmassmann, A.5
  • 58
    • 15444378057 scopus 로고    scopus 로고
    • Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer
    • Neagoe P.E., Lemieux C., and Sirois M.G. Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer. J Biol Chem 280 (2005) 9904-9912
    • (2005) J Biol Chem , vol.280 , pp. 9904-9912
    • Neagoe, P.E.1    Lemieux, C.2    Sirois, M.G.3
  • 59
    • 0037087585 scopus 로고    scopus 로고
    • Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors
    • Kuenen B.C., Rosen L., Smit E.F., Parson M.R., Levi M., Ruijter R., et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 20 (2002) 1657-1667
    • (2002) J Clin Oncol , vol.20 , pp. 1657-1667
    • Kuenen, B.C.1    Rosen, L.2    Smit, E.F.3    Parson, M.R.4    Levi, M.5    Ruijter, R.6
  • 61
    • 33947288597 scopus 로고    scopus 로고
    • Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions
    • Rini B.I. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res 13 (2007) 1098-1106
    • (2007) Clin Cancer Res , vol.13 , pp. 1098-1106
    • Rini, B.I.1
  • 63
    • 34648827568 scopus 로고    scopus 로고
    • Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis
    • van Heeckeren W.J., Sanborn S.L., Narayan A., Cooney M.M., McCrae K.R., Schmaier A.H., et al. Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis. Curr Opin Hematol 14 (2007) 468-480
    • (2007) Curr Opin Hematol , vol.14 , pp. 468-480
    • van Heeckeren, W.J.1    Sanborn, S.L.2    Narayan, A.3    Cooney, M.M.4    McCrae, K.R.5    Schmaier, A.H.6
  • 64
    • 0034074561 scopus 로고    scopus 로고
    • Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors
    • Perletti G., Concari P., Giardini R., Marras E., Piccinini F., Folkman J., et al. Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors. Cancer Res 60 (2000) 1793-1796
    • (2000) Cancer Res , vol.60 , pp. 1793-1796
    • Perletti, G.1    Concari, P.2    Giardini, R.3    Marras, E.4    Piccinini, F.5    Folkman, J.6
  • 65
    • 0027970092 scopus 로고
    • Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
    • O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 (1994) 315-328
    • (1994) Cell , vol.79 , pp. 315-328
    • O'Reilly, M.S.1    Holmgren, L.2    Shing, Y.3    Chen, C.4    Rosenthal, R.A.5    Moses, M.6
  • 66
    • 33747072903 scopus 로고    scopus 로고
    • Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors
    • Kulke M.H., Bergsland E.K., Ryan D.P., Enzinger P.C., Lynch T.J., Zhu A.X., et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 24 (2006) 3555-3561
    • (2006) J Clin Oncol , vol.24 , pp. 3555-3561
    • Kulke, M.H.1    Bergsland, E.K.2    Ryan, D.P.3    Enzinger, P.C.4    Lynch, T.J.5    Zhu, A.X.6
  • 67
    • 29844452745 scopus 로고    scopus 로고
    • Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University
    • Kurup A., Lin C.W., Murry D.J., Dobrolecki L., Estes D., Yiannoutsos C.T., et al. Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University. Ann Oncol 17 (2006) 97-103
    • (2006) Ann Oncol , vol.17 , pp. 97-103
    • Kurup, A.1    Lin, C.W.2    Murry, D.J.3    Dobrolecki, L.4    Estes, D.5    Yiannoutsos, C.T.6
  • 68
    • 0037151364 scopus 로고    scopus 로고
    • Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy
    • Vansteenkiste J., Pirker R., Massuti B., Barata F., Font A., Fiegl M., et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94 (2002) 1211-1220
    • (2002) J Natl Cancer Inst , vol.94 , pp. 1211-1220
    • Vansteenkiste, J.1    Pirker, R.2    Massuti, B.3    Barata, F.4    Font, A.5    Fiegl, M.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.